Food & Health
Eli Lilly and Company (LLY) announced positive Phase 3 results for its eczema drug lebrikizumab in pediatric patients, showing sustained skin clearance for up to four years1. The breakthrough marks the first selective IL-13 inhibitor to deliver positive outcomes in patients aged six months to 18 years...
General Mills (GIS) reaffirmed its fiscal 2026 outlook Wednesday despite persistent pressure from consumer...
Regenxbio Inc (RGNX.O) said Wednesday its experimental gene therapy for Duchenne muscular dystrophy showed...
McDonald’s Corp (MCD) plans to launch menu items priced at $3 or less starting in April, alongside...
The FDA approved leucovorin for cerebral folate deficiency affecting fewer than one in a million people,...
Pfizer (PFE.N) said its experimental eczema drug tilrekimig met the main goal in a mid-stage trial, sending...
GlaxoSmithKline (GSK.L) agreed to sell global rights to its experimental liver disease drug linerixibat...
Trending
CATEGORIES
Categories
SIGNUP TO OUR NEWSLETTER
Subscribe
Get breaking market insights directly to your inbox